Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06005220
Registration number
NCT06005220
Ethics application status
Date submitted
7/08/2023
Date registered
22/08/2023
Titles & IDs
Public title
SBD121, a Synbiotic Medical Food for RA Management
Query!
Scientific title
A Randomised, Double Blind Placebo-controlled Trial Evaluating the Medical Food Synbiotic SBD121, Versus Placebo for the Clinical Dietary Management of Early Rheumatoid Arthritis.
Query!
Secondary ID [1]
0
0
SOL-SYNBIOTIC-2023
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - SBD121
Other interventions - Placebo
Active comparator: SBD121 Medical Food - Two capsules administered twice daily with food
Placebo comparator: Placebo - Two capsules administered twice daily with food
Other interventions: SBD121
Medical Food
Other interventions: Placebo
Placebo
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
American College of Rheumatology 20 (ACR-20)
Query!
Assessment method [1]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 16
Query!
Timepoint [1]
0
0
16 Weeks
Query!
Secondary outcome [1]
0
0
Safety by Adverse Events
Query!
Assessment method [1]
0
0
Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs)
Query!
Timepoint [1]
0
0
16-weeks
Query!
Secondary outcome [2]
0
0
Tolerability by GITQ
Query!
Assessment method [2]
0
0
Frequency and severity of GI symptoms (e.g., gas, abdominal pain, bloating) as assessed by the Gastrointestinal Tolerability Questionnaire (GITQ) score at each timepoint compared to placebo.
Query!
Timepoint [2]
0
0
16-weeks
Query!
Secondary outcome [3]
0
0
American College of Rheumatology 20 (ACR-20)
Query!
Assessment method [3]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 8
Query!
Timepoint [3]
0
0
8 weeks
Query!
Secondary outcome [4]
0
0
American College of Rheumatology 50 (ACR-50)
Query!
Assessment method [4]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR50 response in the ACR composite score at Week 8, and Week 16
Query!
Timepoint [4]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [5]
0
0
American College of Rheumatology 70 (ACR-70)
Query!
Assessment method [5]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR70 response in the ACR composite score at Week 8, and Week 16
Query!
Timepoint [5]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [6]
0
0
Disease Activity Score 28 - Eosinophil Sedimentation Rate (DAS28 - ESR)
Query!
Assessment method [6]
0
0
Evaluate the dietary management of arthritis by the percentage change from baseline value in the Activity Score-28 (DAS-28) with ESR (DAS-28-ESR), and the individual components that make up the DAS-28-ESR \[Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus Erythrocyte Sedimentation Rate (ESR)\], at 8 and 16 weeks
Query!
Timepoint [6]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [7]
0
0
Disease Activity Score 28 - C-Reactive Protein (DAS28 - CRP)
Query!
Assessment method [7]
0
0
Evaluate the dietary management of arthritis by the percentage change from baseline value in the DAS-28 with CRP score and the individual components that make up the DAS-28 CRP Score \[Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus C-Reactive Protein (CRP)\], at 8 and 16 weeks
Query!
Timepoint [7]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [8]
0
0
Disease Activity Score 28 - Eosinophil Sedimentation Rate - Low Disease Activity (DAS28 - ESR - LDA)
Query!
Assessment method [8]
0
0
Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Low Activity defined as DAS-28-ESR Score \< 3.2, at 8 and 16 weeks
Query!
Timepoint [8]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [9]
0
0
Disease Activity Score 28 - C-Reactive Protein - Low Disease Activity (DAS28 - CRP LDA)
Query!
Assessment method [9]
0
0
Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Low Activity, defined as DAS-28-CRP Score \< 3.2, at 8 and 16 weeks
Query!
Timepoint [9]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [10]
0
0
Disease Activity Score 28 - Eosinophil Sedimentation Rate - Remission (DAS28 - ESR Remission)
Query!
Assessment method [10]
0
0
Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Remission defined as DAS-28-ESR Score \< 2.6, at 8 and 16 weeks
Query!
Timepoint [10]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [11]
0
0
Disease Activity Score 28 - C-Reactive Protein - Remission (DAS28 - CRP Remission)
Query!
Assessment method [11]
0
0
Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Remission, defined as DAS-28-CRP Score \< 2.6, at 8 and 16 weeks
Query!
Timepoint [11]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [12]
0
0
C-Reactive Protein (CRP)
Query!
Assessment method [12]
0
0
Evaluate the dietary management of arthritis by the improvement in CRP from baseline
Query!
Timepoint [12]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [13]
0
0
Eosinophil Sedimentation Rate (ESR)
Query!
Assessment method [13]
0
0
Evaluate the dietary management of arthritis by the improvement in ESR from baseline
Query!
Timepoint [13]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [14]
0
0
Zonulin
Query!
Assessment method [14]
0
0
Evaluate improvement in gastrointestinal permeability by improvement in Zonulin from baseline
Query!
Timepoint [14]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [15]
0
0
Reduce or discontinue use of oral corticosteroids
Query!
Assessment method [15]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral corticosteroids, at 8 and 16 weeks
Query!
Timepoint [15]
0
0
8-weeks, 16-weeks
Query!
Secondary outcome [16]
0
0
Reduce or discontinue use of oral NSAIDs
Query!
Assessment method [16]
0
0
Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral NSAIDs, at 8 and 16 weeks
Query!
Timepoint [16]
0
0
8-weeks, 16-weeks
Query!
Eligibility
Key inclusion criteria
1. Willing and able to provide written informed consent prior to the performance of any study-specific procedure and willing to comply with the protocol and report on compliance and side effects during study period.
2. Male or female aged 18 - 75 years inclusive at the time of consent.
3. The participant must have newly diagnosed RA, not exceeding 1-year from diagnosis
4. The participant must have been taking methotrexate (MTX) for treatment of RA for = 75 days before baseline, or will be commencing MTX at the same time as baseline (within range 15 to 25 mg inclusive, recommended target dose of 20mg).
5. The participant must have active RA meeting classification criteria according to the 2010 ACR/EULAR guidelines with a score equal to or greater than 6/10 at screening (11). (Seropositivity is not required).
6. The participant must be available throughout entire study period, willing and able to attend all scheduled visits and in the opinion of the Investigator be able to understand and comply with planned study procedures.
7. Body Mass Index (BMI) between 18.5 and 40 kg/m2
8. Normal cardiovascular parameters (systolic blood pressure = 150 mm Hg, diastolic blood pressure = 90 mm Hg). One re-test is permitted.
9. Women of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test pre-first administration, on Day 1, and must agree to remain sexually abstinent, or use medically effective contraception (refer to Appendix 11.1), or have a partner who is sterile or same-sex, from Screening until end of study. Males must not be planning to father children or donate sperm for the duration of the study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participant is currently taking any probiotic or prebiotic supplements, or has taken them in the past 7 days, or is unwilling to avoid taking probiotic/prebiotic supplements for the duration of the study.
2. Participant has any known or suspected allergies to probiotics or prebiotics.
3. Participant has taken oral or parenteral antibiotics within 21 days of screening, requires antibiotics pre-first dose, or is likely to require antibiotics during the study period.
4. Participant has undergone major surgery within last 3-months before screening or planned during the study period
5. Participant is a current smoker and/or uses nicotine replacement therapies (including vaping).
6. Participant has a past or current history of drug and/or alcohol abuse at the time of enrolment (the use of illegal drugs or the use of prescription or over-the-counter drugs or alcohol for purposes other than those for which they are meant to be used, or in excessive amounts).
7. Participant has a known history of any of the following (according to Investigator judgement and/or participant report):
1. Gastric or intestinal dysmotility, slowed transit time, pancreatitis, or inflammatory bowel disease
2. Known Hepatitis B or Hepatitis C infection, cirrhosis or chronic liver disease
3. Underlying structural heart disease or previous history of endocarditis or valve replacement
4. Rheumatic disease other than rheumatoid arthritis, including but not limited to psoriasis, spondyloarthritis, systemic lupus erythematosus, multiple sclerosis
5. Immunosuppressed, including: known HIV positive; solid organ or stem cell transplant recipient; taking any oral or parenteral immunosuppressive therapy; neutrophil count <500/mm3; or anticipated drop in the neutrophil count to <500/mm3
6. Any malignancy, with the exception of non-melanoma skin cancers, or other cancer more than 5-years ago
7. Active tuberculosis (TB) within 3-months prior to Screening
8. Any infection requiring hospitalisation, or as otherwise judged clinically significant, within 3-months prior to Screening
8. Presence of any of the following active conditions at Screening, or within 72 hours of the first administration of study test article:
1. Clinically significant abnormal vital signs or physical examination abnormalities (other than those related to RA, such as joint swelling)
2. Febrile illness (temp. > 37.5 degrees Celsius), or one or more episodes of diarrhoea within 72 hours of the first dose of study test article
3. Acute abdomen, colitis, or active GI disease
4. Septicaemia or bacteraemia
5. Uncontrolled diabetes mellitus, based on medical history and in response to query 'is your diabetes under control?'.
9. Current treatment with any Disease Modifying Arthritis Drug (DMARD) other than methotrexate including but not limited to, hydroxychloroquine, sulfasalazine, and minocycline leflunomide, gold compounds, azathioprine, or cyclosporine will be exclusionary if used within 30 days prior to randomisation.
10. Current or past treatment with any biologic agent including but not limited to tumor necrosis factor (TNF) inhibitors: etanercept, infliximab, adalimumab; interleukin 1 (IL-1) inhibitors: anakinra; lymphocyte directed: abatacept, rituximab; Janus kinase (JAK) inhibitors: tofacitinib; interleukin 17 (IL-17) inhibitors; Interleukin 23 (IL-23) inhibitors.
11. Corticosteroid use from 30 days prior to randomisation until final assessment visit will be exclusionary, with the following exceptions:
1. Oral corticosteroids in low doses (= 10 mg/d prednisone or equivalent) will be allowed if stable for 1-month prior to randomisation. Reduction of dose or use of oral corticosteroids is permissible throughout the study.
2. Topical, inhaled, or intranasal steroids are permitted
3. Past use of oral or parenteral (> 10 mg/d prednisone or equivalent) corticosteroids is allowed if not used within 1-month prior to randomisation.
12. Women only - pregnant, planning on becoming pregnant during the trial, breastfeeding, positive urine pregnancy test during Screening or within 24 hours of first administration of study test article.
13. Any of the following abnormal findings on Screening or Baseline laboratory tests (one re-test per timepoint permitted):
1. White blood cells (WBCs) < lower limit of normal (LLN) or > upper limit of normal (ULN). If WBC is documented within normal range prior to commencing steroids and is deemed by the Investigator as elevated at screening due to recent addition of these drugs and not related to any other comorbidities, then may be suitable to proceed.
2. Neutrophils < 1500/µl (1.5 x109/L)
3. Platelets < 100 x 10³/µl (100 x 109/L)
4. Haemoglobin < 9.0 g/dl (90 g/L)
5. Serum Creatinine > 1.5 x ULN
6. Glomerular filtration rate (GFR) of < or = 40 mL/minute
7. Aspartate aminotransferase (AST) > 3 x ULN
8. Alanine aminotransferase (ALT) > 3 x ULN
9. Total Bilirubin > 1.5 x ULN
14. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study
15. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/09/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/09/2024
Query!
Actual
Query!
Sample size
Target
140
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Paratus Clinical Canberra - Canberra
Query!
Recruitment hospital [2]
0
0
Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [3]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [4]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [5]
0
0
Genesis Research Services - Newcastle
Query!
Recruitment hospital [6]
0
0
BJC Health - Parramatta
Query!
Recruitment hospital [7]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [8]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [9]
0
0
Western Health - St. Albans
Query!
Recruitment hospital [10]
0
0
Latrobe Regional Hospital - Traralgon
Query!
Recruitment hospital [11]
0
0
Linear Clinical Trials - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2606 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [3]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [4]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [5]
0
0
2292 - Newcastle
Query!
Recruitment postcode(s) [6]
0
0
2150 - Parramatta
Query!
Recruitment postcode(s) [7]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [8]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [9]
0
0
3021 - St. Albans
Query!
Recruitment postcode(s) [10]
0
0
3844 - Traralgon
Query!
Recruitment postcode(s) [11]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Nelson
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Solarea Bio, Inc
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid arthritis (RA).
Query!
Trial website
https://clinicaltrials.gov/study/NCT06005220
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Maureen Stanley
Query!
Address
0
0
Southern Star Research Pty Ltd.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Eric Schott
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
585-704-8069
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06005220